PALO ALTO, Calif.--(BUSINESS WIRE)--April 20, 2006--Target Discovery, Inc. announces today a broad collaboration with researchers at The University of Texas M. D. Anderson Cancer Center to develop a new generation of cancer diagnostic assays. The collaboration will initially focus on breast cancer, followed by other cancer areas with serious unmet diagnostic needs. Scientists at Target Discovery will use the company’s patented mass defect technology, Isotope-Differentiated Binding Energy Shift Tags (IDBEST(TM)), to validate clinical protein biomarkers at the isoform level, using retrospective patient samples provided by M. D. Anderson Cancer Center. Target Discovery will then integrate selected protein isoform biomarkers into its proprietary Isonostics(TM) technology, to develop clinical assays designed to assist clinicians in differentiating between invasive and non-invasive forms of breast cancer.
